Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn (HORACE)

• ClinicalTrials.gov Identifier: NCT05092685
• Recruitment Status: Not yet recruiting
• First Posted: October 25, 2021
• Last Update Posted: October 25, 2021
• Sponsor: University College, London
• Information provided by (Responsible Party): University College, London

Study Description

Brief Summary:

Ornithine transcarbamylase deficiency (OTCD) is an inherited metabolic liver disease which means that the body cannot maintain normal levels of ammonia. Ammonia levels can rise (called hyperammonaemic decompensations) which can be life-threatening and may result in impaired neurological development in children. OTCD is a rare genetic disorder characterised by complete or partial lack of the enzyme ornithine transcarbamylase (OTC).

Condition or disease	Intervention/treatment	Phase
Ornithine Transcarbamylase Deficiency	Genetic: AAVLK03hOTC	Phase 1; Phase 2

Detailed Description:

OTC is a key element of the urea cycle, which is how the liver breaks down and removes extra nitrogen from the body. For people with OTCD the extra nitrogen builds up in the form of excess ammonia (hyperammonemia) in the blood.

Ammonia is toxic and people with OTCD suffer 'hyperammonaemic decompensations' when ammonia levels in the blood rise too high. The symptoms of these hyperammonaemic decompensations include vomiting, impaired movement, and progressive lethargy. If left untreated these hyperammonaemic decompensations may result in life-threatening complications or coma. OTCD is managed with drugs that reduce the amount of ammonia in the blood (ammonia-scavenging drugs) and a low protein diet. However, sometimes hyperammonaemic decompensations still occur.

Liver transplants for people with OTCD can be life-saving but there may be a long wait for a suitable liver and neurological damage may occur before a liver transplant is possible.

The HORACE study is testing a new gene therapy (AAVLK03hOTC) which specifically targets the liver so that it can start making OTC. The investigators hope that a single injection of gene therapy for children with OTCD could help the liver work normally and reduce hyperammonaemic decompensations and their associated risks.

This gene-therapy treatment could serve as a 'bridge-to-transplant' where children could grow up in a metabolically stable condition until a liver transplant is possible. This could minimise longer-term neurological damage caused by hyperammonaemic decompensations.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 12 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I/II Open Label, Multicentre Clinical Trial to Assess Safety and Efficacy of AAVLK03hOTC for Paediatric Patients With Ornithine Transcarbamylase Deficiency.
• Estimated Study Start Date: February 1, 2022
• Estimated Primary Completion Date: June 30, 2024
• Estimated Study Completion Date: June 30, 2028

Arms and Interventions

Arm	Intervention/treatment
Experimental: AAVLK03hOTC (also known as ssAAV-LK03.hAAT.hcoOTC); Dose escalation in three groups from 6x10^11vg/kg (low dose), 2x10^12vg/kg (intermediate dose) to 6x10^12vg/kg (high dose). Dose expansion in a fourth group with the best acceptable safety:efficacy ratio	Genetic: AAVLK03hOTC; Peripheral intravenous infusion of AAVLK03hOTC.; Other Name: Also known as ssAAV-LK03.hAAT.hcoOTC

Outcome Measures

Primary Outcome Measures :

1. Safety - adverse events [ Time Frame: 12 months post-infusion ]
   Incidence of adverse events (AEs), treatment-related adverse events and serious adverse events (SAEs) for each dosing group assessed by severity and relationship to study product.

Secondary Outcome Measures :

1. Safety outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline level of transaminases (AST and ALT).
2. Safety outcomes [ Time Frame: Over 12 months post-infusion ]
   Change from baseline level of humoral and cellular immune responses the AAV-LK03 capsid.
3. Safety outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline level of cellular immune against hOTC.
4. Safety outcomes [ Time Frame: Over 12 months post-infusion ]
   • Viral shedding: plasma/saliva/urine/stool samples.
5. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

   Clinical parameters

   • Monitoring of number and frequency of hyperammonaemic episodes and hospitalisations

6. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

   Clinical parameters

   • Monitoring of daily protein allowance

7. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

   Clinical parameters

   • Monitoring number of ammonia scavenger drugs.

8. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

   Biological parameters

   • Change from baseline levels of glutamine and glutamate.

9. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

   Biological parameters

   • Change from baseline levels of ammonaemia.

10. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

    Biogical parameters

    • Change from baseline levels of urine orotic acid.

11. Efficacy outcomes [ Time Frame: Over 12 months post-infusion ]

    Functional parameters:

    • Change from baseline rate of ureagenesis rate.

Other Outcome Measures:

1. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline neurocognitive assessment, as measured by the Bayley - III for participants aged 6months to 3 years
2. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline neurocognitive assessment as measured WPPSI-IV for participants aged 2 years 6 months to 7 years 7 months
3. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline neurocognitive assessment as measured by the WISC-V for participants aged 6 years to 16 years and 11months
4. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline behavioural assessment as measured by the Child Behaviour Checklist
5. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   • Change from baseline in adaptive functioning, as measured by the Vineland
6. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   Change in quality of life, as measured by the Paediatric Quality of Life inventory
7. Exploratory outcomes [ Time Frame: At 12 months post-infusion ]
   Quantification of viral vector integration in hepatocytes, from liver samples
8. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   • Assessment of OTC enzymatic activity
9. Exploratory outcomes [ Time Frame: Over 12 months post-infusion ]
   Assessment of vector genome copy numbers in liver samples

Eligibility Criteria

• Ages Eligible for Study: 0 Days to 16 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patient (male or female) aged ≤16 years at time of written informed consent. For the dose escalation phase patients must be aged 6-16, for the dose expansion phase patients must be aged 0-16 (at the time of written informed consent).
2. OTC deficiency confirmed via enzymatic or molecular analysis. This may include identification of pathogenic mutations or liver OTC activity that is <20% of normal activity.
3. Patient has severe disease defined by reduced protein allowance and prescribed at least one ammonia scavenger drug.
4. Patient (if capable of signing) and parents or legal representative have signed a written informed consent form.
5. Females of childbearing potential must have a negative pregnancy test in serum or urine at the screening and Day 0 infusion visits, and use an adequate contraception method from the screening visit until 4 weeks after the first negative plasma sample monitoring vector genomes copies or the week 52 visit, whatever comes first.
6. Sexually active boys must use an adequate contraception method (abstinence or use of condom with spermicide) from at least 14 days prior to the infusion and until 4 weeks after the first negative plasma sample monitoring vector genomes copies or the week 52 visit, whatever comes first.
7. Patient's ammonia level at baseline visit (pre-gene therapy infusion) is <100µmol/L and is within the range of historical ammonia levels obtained when the patient was clinically stable.
8. Patient has been on a stable dose of ammonia scavenger and stable protein allowance for the last 4 weeks at the baseline visit.
9. Patient is willing to commit to an additional 4 years of long-term safety follow-up.

Exclusion criteria:

1. Titres of the neutralising antibodies against AAV-LK03 >1:5 serum dilution.
2. Significant hepatic inflammation as evidenced by the following laboratory abnormalities: alanine aminotransferase or aspartate aminotransferase or bilirubin >2 x upper limit of normal (ULN), alkaline phosphatase >3 x ULN.
3. Evidence of severe unexplained liver disease including but not limited to liver malignancy, liver cirrhosis, or acute liver failure.
4. Evidence of active hepatitis B or C virus (HBV and HCV respectively) documented by hepatitis B surface antigen (HBsAg) or HCV RNA positivity.
5. Positive PCR for human immunodeficiency virus (HIV).
6. Liver transplant including hepatocytes/cells infusion.
7. Current participation in another clinical trial of an investigational medicinal product or medical device, or participation within previous 12 months.
8. Patient has contraindication to immunosuppression.
9. Active infection (bacterial or viral).
10. Pregnant or breastfeeding females.
11. Patients with other serious underlying medical conditions including malignancy and severe (≥ grade 3) functional organ impairment (liver, kidney, respiratory) according to CTCAE v5.0. For neurological symptoms considered as sequelae of previous hyperammonaemic decompensation and which are considered as stable (i.e. not evolving), a grade 3 will be acceptable. Grade 4 and 5 will preclude inclusion.
12. Patients with any other significant condition or disability that, in the investigator opinion, may interfere with the patient's optimal participation in the study.

Contacts and Locations

Contacts

Contact: Trial Manager; +44 (0) 20 7907 4669; cctu.horace@ucl.ac.uk

Sponsors and Collaborators

University College, London

More Information

• Responsible Party: University College, London
• ClinicalTrials.gov Identifier: NCT05092685
• Other Study ID Numbers: 18/0123
• First Posted: October 25, 2021
• Last Update Posted: October 25, 2021
• Last Verified: October 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided
• Plan Description: Written requests will be considered by the HORACE Trial Management Group.

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Ornithine Carbamoyltransferase Deficiency Disease; Urea Cycle Disorders, Inborn; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Amino Acid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases